SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today highlighted clinical, safety and translational data for AlloNK (also known as AB-101), an allogeneic, off-the-shelf, non-genetically modified natural killer (NK) cell therapy candidate, presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London.
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20close-up%20shot%20of%20a%20Broadcom%20chip%20by%20g0d4ather%20via%20Adobe%20Stock.jpeg)
/A%20close-up%20of%20a%20SpaceX%20sign%20by%20Sundry%20Photography%20via%20Adobe%20Stock.jpeg)
/Apple%20logo%20-%20by%20Pexels%20via%20Pixabay.jpg)